VRAX
Virax Biolabs Group Ltd
Key Financials
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 6-K | 6/24/2026 | View on SEC |
| 6-K | 6/12/2026 | View on SEC |
| 6-K | 5/26/2026 | View on SEC |
| 6-K | 5/22/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 6-K | 4/14/2026 | View on SEC |
| 6-K | 4/10/2026 | View on SEC |
| 3 | 3/31/2026 | View on SEC |
| 3 | 3/20/2026 | View on SEC |
| 6-K | 3/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VRAX |
| Company Name | Virax Biolabs Group Ltd |
| CIK | 1885827 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Non-accelerated filer Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | other |
| Fiscal Year End | 0331 |
| State of Incorporation | E9 |
| Phone | 44 020 7788 7414 |